Showing 1 posts of 1 posts found.
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease